The neo-open reading frame peptides that comprise the tumor framome are a rich source of neoantigens for cancer immunotherapy.


Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
04 Apr 2024
Historique:
accepted: 27 03 2024
received: 21 02 2023
revised: 22 09 2023
medline: 4 4 2024
pubmed: 4 4 2024
entrez: 4 4 2024
Statut: aheadofprint

Résumé

Identification of immunogenic cancer neoantigens as targets for therapy is challenging. Here, we integrate cancer whole genome and long-read transcript sequencing to identify the collection of novel open reading frame peptides (NOPs) expressed in tumors, termed the framome. NOPs represent tumor-specific peptides that are different from wild-type proteins and may be strongly immunogenic. We describe an uncharacterized class of hidden NOPs, which derive from structural genomic variants involving an upstream protein coding gene driving expression and translation of non-coding regions of the genome downstream of a rearrangement breakpoint. NOPs represent a vast amount of possible neoantigens particularly in tumors with many (complex) structural genomic variants and a low number of missense mutations. We show that NOPs are immunogenic and epitopes derived from NOPs can bind to MHC class I molecules. Finally, we provide evidence for the presence of memory T-cells specific for hidden NOPs in lung cancer patient peripheral blood.

Identifiants

pubmed: 38573707
pii: 742916
doi: 10.1158/2326-6066.CIR-23-0158
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Michael V Martin (MV)

CureVac Netherlands B.V., Amsterdam, Netherlands.

Salvador Aguilar-Rosas (S)

CureVac Netherlands B.V., Amsterdam, Netherlands.

Katka Franke (K)

CureVac Netherlands B.V., Amsterdam, Netherlands.

Mark Pieterse (M)

CureVac Netherlands B.V., Amsterdam, Netherlands.

Jamie van Langelaar (J)

CureVac Netherlands B.V., Amsterdam, Netherlands.

Renee Rce Schreurs (RR)

CureVac Netherlands B.V., Amsterdam, Netherlands.

Maarten F Bijlsma (MF)

Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands.

Jan Koster (J)

Amsterdam UMC, University of Amsterdam, Amsterdam, NH, Netherlands.

Wim Timens (W)

University of Groningen and University Medical Center Groningen, Groningen, Netherlands.

Mustafa Khasraw (M)

Duke University, Durham, NC, United States.

David M Ashley (DM)

Duke University, Durham, NC, United States.

Stephen T Keir (ST)

Duke Medical Center, Durham, NC, United States.

Christian H Ottensmeier (CH)

University of Southampton, Liverpool, Merseyside, United Kingdom.

Emma V King (EV)

University Hospitals Dorset, Poole, United Kingdom.

Joanne Verheij (J)

Amsterdam UMC, Amsterdam, Netherlands.

Cynthia Waasdorp (C)

Amsterdam UMC, location AMC, Amsterdam, Netherlands.

Peter J M Valk (PJM)

Erasmus MC, Rotterdam, Netherlands.

Sem Ag Engels (SA)

The Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.

Ellen Oostenbach (E)

The Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.

Jip T van Dinter (JT)

Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, Netherlands.

Damon A Hofman (DA)

Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.

Juk Yee Mok (JY)

Sanquin Reagents, Sanquin, Amsterdam, Netherlands.

Wim J E van Esch (WJE)

CureVac Netherlands B.V., Amsterdam, Netherlands.

Hanneke Wilmink (H)

Academic Medical Center, Amsterdam, Netherlands.

Kim Monkhorst (K)

Netherlands Cancer Institute, Amsterdam, Netherlands.

Henk M W Verheul (HMW)

Erasmus MC, Rotterdam, Netherlands.

Dennis Poel (D)

Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.

T Jeroen N Hiltermann (TJN)

University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

Léon C van Kempen (LC)

University Medical Center Groningen, Groningen, I am not in the U.S. or Canada, Netherlands.

Harry Jm Groen (HJ)

University of Groningen, Groningen, Netherlands.

Joachim G J V Aerts (JGJV)

Erasmus MC Cancer Institute, Rotterdam, Netherlands.

Sebastiaan van Heesch (S)

Princess Máxima Center, Utrecht, Utrecht, Netherlands.

Bob Lowenberg (B)

Erasmus Medical Centre Rotterdam.

Ronald Plasterk (R)

CureVac Netherlands B.V., Amsterdam, Netherlands.

Wigard P Kloosterman (WP)

CureVac Netherlands B.V., Amsterdam, Netherlands.

Classifications MeSH